Tairx, Inc.
Clinical trials sponsored by Tairx, Inc., explained in plain language.
A Taiwanese biopharmaceutical company developing oncology and CNS drugs.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
New triple therapy aims to shrink untreatable liver tumors
Disease control Recruiting nowThis study tests a new drug (CVM-1118) combined with an immunotherapy (sintilimab) and a procedure that blocks the tumor's blood supply (TACE) in people with liver cancer that cannot be cured but hasn't spread. About 40 adults will receive all three treatments to see if the combi…
Phase: PHASE2 • Sponsor: TaiRx, Inc. • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
New hope for advanced liver cancer: drug duo tested in phase 2 trial
Disease control Recruiting nowThis study tests a new drug called CVM-1118 combined with an immunotherapy drug (nivolumab) in people with advanced liver cancer that cannot be removed by surgery. About 95 adults will take part to see if the combination shrinks tumors and how long any benefit lasts. The goal is …
Phase: PHASE2 • Sponsor: TaiRx, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New oral gel could tame tough tumors with fewer side effects
Disease control Recruiting nowThis early-stage study tests an oral gel called TRX-920 in 30 people with advanced solid tumors that no longer respond to standard treatments. The gel contains SN38, a powerful anti-cancer drug, and aims to shrink tumors with fewer side effects than the current IV version. The ma…
Phase: PHASE1 • Sponsor: TaiRx, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC